GoodRx director granted 4,642 stock units

Bruehlman Ronald E reported acquisition or exercise transactions in this Form 4 filing.

Rhea-AI Filing Summary

Bruehlman Ronald E reported acquisition or exercise transactions in this Form 4 filing.

GoodRx Holdings, Inc. director Ronald E. Bruehlman received a grant of 4,642 deferred stock units, each representing a contingent right to one share of Class A common stock, at no cash cost. The units vest 2% on May 31, 2026, with the remaining 98% vesting in substantially equal monthly installments over the following seven months, subject to continued service. The deferred stock units will settle upon the earliest of several events, including December 31, 2031 or separation from service. Following this grant, Bruehlman directly holds 133,918 Class A shares, including this award.

Insider Trade Summary

Grant/Award: 4,642 shares

Grant/Award 1 txn

Insider Bruehlman Ronald E

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Class A Common Stock	4,642	$0.00	$0.00

Holdings After Transaction: Class A Common Stock — 133,918 shares (Direct)

Footnotes (1)

1. F1. Reflects deferred stock units. Each deferred stock unit represents a contingent right to receive one share of Class A common stock. The deferred stock units will vest as to 2% of the underlying shares on May 31, 2026, and the remining 98% will vest in substantially equal monthly installments on last day of each month over the following 7 months, subject to continued service through the applicable vesting date. The deferred stock units will settle on the earliest to occur of the following events (i) December 31, 2031; (ii) Separation from Service; (iii) a Change in Control; (iv) death; or (v) Disability (each, as defined under the GoodRx Holdings, Inc. Deferred Compensation Plan for Directors).

Key Figures

Deferred stock units granted: 4,642 units Shares after transaction: 133,918 shares Grant price: $0.0000 per unit +3 more

6 metrics

Deferred stock units granted 4,642 units Equity award of deferred stock units to director

Shares after transaction 133,918 shares Total Class A shares directly held after grant

Grant price $0.0000 per unit Reported price for deferred stock unit grant

Initial vesting tranche 2% on May 31, 2026 First vesting portion of deferred stock units

Remaining vesting 98% over 7 months Substantially equal monthly vesting after initial tranche

Latest settlement date December 31, 2031 Latest possible settlement date for deferred units

Key Terms

deferred stock units, Separation from Service, Change in Control, Disability, +1 more

5 terms

deferred stock units financial

"Reflects deferred stock units. Each deferred stock unit represents a contingent right to receive one share of Class A common stock."

Deferred stock units are promises from a company to give an employee shares of stock at a future date, often after certain conditions are met or after leaving the company. They function like a form of delayed compensation, allowing employees to earn shares over time. For investors, they represent potential future ownership in the company, but do not provide immediate voting rights or dividends until the shares are actually received.

Separation from Service financial

"The deferred stock units will settle on the earliest to occur of the following events (i) December 31, 2031; (ii) Separation from Service; (iii) a Change in Control;"

Change in Control financial

"The deferred stock units will settle on the earliest to occur of the following events ... (iii) a Change in Control; (iv) death; or (v) Disability"

A "change in control" occurs when the ownership or management of a company shifts significantly, such as through a merger, acquisition, or sale of a large part of its assets. This change can impact how the company is run and may influence its future direction. For investors, it matters because it can affect the company's stability, strategy, and value, often signaling potential changes in investment risk or opportunity.

Disability financial

"The deferred stock units will settle on the earliest to occur of ... (iv) death; or (v) Disability (each, as defined under the GoodRx Holdings, Inc."

Deferred Compensation Plan for Directors financial

"Disability (each, as defined under the GoodRx Holdings, Inc. Deferred Compensation Plan for Directors)."

A deferred compensation plan for directors is an arrangement that lets board members postpone receiving part of their pay until a later date—often retirement or a set future time—so the money can grow or be paid under specified conditions. Think of it like directing a portion of your paycheck into a locked savings account that pays out later; investors care because it creates future cash or stock obligations, signals how the company motivates and retains leadership, and can affect shareholder value through timing of payouts or potential dilution.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did GoodRx (GDRX) report for Ronald E. Bruehlman?

GoodRx reported a grant of 4,642 deferred stock units to director Ronald E. Bruehlman. These units are equity compensation, not an open-market purchase, and each unit represents a contingent right to receive one share of Class A common stock at settlement.

How do the 4,642 deferred stock units for GoodRx (GDRX) vest?

The 4,642 deferred stock units vest 2% on May 31, 2026, with the remaining 98% vesting in substantially equal monthly installments over the next seven months. Vesting is conditioned on Bruehlman’s continued service through each applicable vesting date.

When will Ronald E. Bruehlman’s GoodRx (GDRX) deferred stock units settle?

The deferred stock units will settle in shares on the earliest of several events: December 31, 2031, separation from service, a change in control, death, or disability, as defined under the GoodRx Holdings, Inc. Deferred Compensation Plan for Directors.

How many GoodRx (GDRX) shares does Ronald E. Bruehlman hold after this grant?

After this grant, Ronald E. Bruehlman holds 133,918 shares of GoodRx Class A common stock directly. This total includes the 4,642 deferred stock units reported, which represent a contingent right to receive an equivalent number of Class A shares upon settlement.

Did Ronald E. Bruehlman buy or sell GoodRx (GDRX) shares in this Form 4?

This Form 4 shows an acquisition through a grant of 4,642 deferred stock units, not a market buy or sale. The transaction code is “A,” meaning grant or award, with a reported price of $0.0000 per unit as typical for equity compensation.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 05/29/2026 - 05:58 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Bruehlman Ronald E

(Last) (First) (Middle)

C/O GOODRX HOLDINGS, INC.

2701 OLYMPIC BOULEVARD

(Street)

SANTA MONICA CALIFORNIA 90404

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
GoodRx Holdings, Inc. [ GDRX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/27/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Class A Common Stock	05/27/2026		A		4,642(1)	A	$0	133,918	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Reflects deferred stock units. Each deferred stock unit represents a contingent right to receive one share of Class A common stock. The deferred stock units will vest as to 2% of the underlying shares on May 31, 2026, and the remining 98% will vest in substantially equal monthly installments on last day of each month over the following 7 months, subject to continued service through the applicable vesting date. The deferred stock units will settle on the earliest to occur of the following events (i) December 31, 2031; (ii) Separation from Service; (iii) a Change in Control; (iv) death; or (v) Disability (each, as defined under the GoodRx Holdings, Inc. Deferred Compensation Plan for Directors).

Remarks:

	/s/ Gracye Cheng, Attorney-in-Fact for Ronald E Bruehlman	05/29/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)